3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
8
Terminated
2
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Hematologic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
beta-Thalassemia
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Graft vs Host Disease
2
Anemia, Refractory, with Excess of Blasts
2
Virus Diseases
1
Thalassemia
1
Primary Myelofibrosis
1
Non-Malignant Neoplasm
1
Neurofibromatosis 1
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, B-Cell
1
Influenza, Human
1
Fanconi Anemia
1
Cytopenia
1
Chromosome Aberrations
1
Chromosome 7, monosomy
1
Anemia, Sickle Cell
1
Interventions
fludarabine
8
Specimen Handling
8
Cyclophosphamide
7
ruxolitinib
5
Whole-Body Irradiation
5
Stem Cell Transplantation
5
Biopsy
5
Azacitidine
5
venetoclax
4
Tacrolimus
4
Injections
4
Cytarabine
4
Busulfan
4
ivosidenib
3
fludarabine phosphate
3
Thiotepa
3
Mycophenolic Acid
3
Melphalan
3
Cyclosporins
3
CPX-351
3
Blood Specimen Collection
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
luspatercept
2
X-Rays
2
Sirolimus
2
Peripheral Blood Stem Cell Transplantation
2
Methotrexate
2
Liposomes
2
Gemtuzumab
2
Daunorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Myeloproliferative Disorders
×
thymoglobulin
×
Clear all
NCT03852407
2022-10-12
HLA
University of Liege
Phase 2
Recruiting
114 enrolled